Disease Markers

Table of Contents: 2002

  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 462465

Assessment of Normal Variability in Peripheral Blood Gene Expression

Catherine Campbell | Suzanne D. Vernon | ... | Elizabeth R. Unger
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 892374

Utility of the Blood for Gene Expression Profiling and Biomarker Discovery in Chronic Fatigue Syndrome

Suzanne D. Vernon | Elizabeth R. Unger | ... | William C. Reeves
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 565204

Nanometer-Scale Pores: Potential Applications for Analyte Detection and DNA Characterization

John J. Kasianowicz
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 874157

Mechanical Spectral Signatures of Malignant Disease? A Small-Sample, Comparative Study of Continuum vs. Nano-Biomechanical Data Analyses

Jun Liu | Mauro Ferrari
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 856032

Bioassays Based on Molecular Nanomechanics

Arun Majumdar
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 727014

Calcified Nanostructured Silicon Wafer Surfaces for Biosensing: Effects of Surface Modification on Bioactivity

Robert P. Weis | Jean-Luc Montchamp | ... | Tejal A. Desai
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 591527
  • - Foreword

Nanotechnology: Emerging Developments and Early Detection of Cancer. A Two-Day Workshop Sponsored by the National Cancer Institute and the National Institute of Standards and Technology, August 30–31 2001, on the National Institute of Standards and Technology Campus, Gaithersburg, MD, USA

Steven J. Zullo | Sudhir Srivastava | ... | Peter E. Barker
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 496345

Immunohistochemical Expression of Retinoblastoma Gene Product in Normal, Hyperplastic and Malignant Endometrium. Correlation with p53 Protein Expression, c-erbB-2, Hormone Receptors’ Status and Proliferative Activity

E. E. Ioachim | A. C. Goussia | ... | S. Stefanaki
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 647961

Evaluation of Nitric Oxide (NO) Levels in Hepatitis C Virus (HCV) Infection: Relationship to Schistosomiasis and Liver Cirrhosis among Egyptian Patients

Mahmoud Ismail Hassan | Samar Kamal Kassim | ... | Ali Khalifa
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 194075

Surfactant Protein B Intron 4 Variation in German Patients with COPD and Acute Respiratory Failure

Carola Seifart | Alexandra Plagens | ... | Joanna Floros
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 418383

The Stromelysin-1 5A/6A Promoter Polymorphism Is a Disease Marker for the Extent of Coronary Heart Disease

Adelheid Schwarz | Werner Haberbosch | ... | Andreas Gardemann
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 843537

Soluble Inter-Cellular Adhesion Molecule-1 in Urban Asian North Indians: Relationships with Anthropometric and Metabolic Covariates

Astha Sethi | Anoop Misra | ... | Naval Kishore Vikram
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 156359

Evaluation of Blood Units with Isolated Anti HBC for the Presence of HBV DNA

Abdel-Rahman N. Zekri | Azza A. Awlia | ... | Gamal M. Mabrouk
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 505397

Shotgun Proteomics and Biomarker Discovery

W. Hayes McDonald | John R. Yates
  • Disease Markers -
  • Special Issue
  • Volume 18
  • - Article ID 178798

Comprehensive phenotyping and biological marker discovery

Aaron B. Kantor
Disease Markers
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision131 days
Acceptance to publication42 days
CiteScore3.700
Journal Citation Indicator-
Impact Factor-
 Submit Check your manuscript for errors before submitting

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.